

PubMed

**Format:** Abstract**Full text links**Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6.

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex[®]): A Review in Multiple Sclerosis-Related Spasticity.

Keating GM¹.

Author information

Abstract

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (THC/CBD, Sativex[®], nabiximols) is available in numerous countries worldwide for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity in patients who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. Twelve weeks' therapy with THC/CBD improved MS-related spasticity in patients with an inadequate response to other anti-spasticity agents who had undergone a successful initial trial of THC/CBD therapy, according to the results of a pivotal phase 3 trial. Improvements in spasticity were maintained in the longer term with THC/CBD with no evidence of dose tolerance, and results of real-world studies confirm the effectiveness of THC/CBD in everyday clinical practice. Improvements in health-related quality of life and activities of daily living were also seen with THC/CBD. THC/CBD is generally well tolerated; adverse effects such as dizziness may occur whilst the THC/CBD dosage is being optimized. THC/CBD has low abuse potential and a low risk of psychoactive effects. In conclusion, THC/CBD oromucosal spray is a useful option for the treatment of MS-related spasticity not completely relieved with current anti-spasticity medication.

PMID: 28293911 DOI: [10.1007/s40265-017-0720-6](https://doi.org/10.1007/s40265-017-0720-6)

[Indexed for MEDLINE]

**Publication type, MeSH terms, Substances**

LinkOut - more resources

